Found: 14
Select item for more details and to access through your institution.
External quality assessment of HIV-1 DNA quantification assays used in the clinical setting in Italy.
- Published in:
- Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-07196-2
- By:
- Publication type:
- Article
Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults.
- Published in:
- Infectious Diseases & Therapy, 2019, v. 8, n. 3, p. 453, doi. 10.1007/s40121-019-0256-z
- By:
- Publication type:
- Article
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA.
- Published in:
- Journal of the International AIDS Society, 2014, v. 17, p. n/a, doi. 10.7448/IAS.17.4.19791
- By:
- Publication type:
- Article
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study.
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0156523
- By:
- Publication type:
- Article
Quantification of Total HIV DNA as a Marker to Measure Viral Reservoir: Methods and Potential Implications for Clinical Practice.
- Published in:
- Diagnostics (2075-4418), 2022, v. 12, n. 1, p. 39, doi. 10.3390/diagnostics12010039
- By:
- Publication type:
- Article
Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Rome, Italy during the COVID-19 Outbreak.
- Published in:
- Diagnostics (2075-4418), 2021, v. 11, n. 7, p. 1154, doi. 10.3390/diagnostics11071154
- By:
- Publication type:
- Article
Response to BNT162b2 mRNA COVID-19 vaccine of ART-experienced people living with HIV: a prospective analysis from a single-center study in Rome, Italy.
- Published in:
- Infezioni in Medicina, 2023, v. 31, n. 3, p. 359, doi. 10.53854/liim-3103-9
- By:
- Publication type:
- Article
Comparison of HIV-DNA decay in naïve patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
- Published in:
- Infezioni in Medicina, 2020, v. 28, n. 3, p. 461
- By:
- Publication type:
- Article
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
- Published in:
- Infezioni in Medicina, 2018, v. 26, n. 4, p. 336
- By:
- Publication type:
- Article
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
- Published in:
- 2016
- By:
- Publication type:
- Letter